FDA Approves New Non-Hormonal Pill for Menopause Hot Flashes and Night Sweats

New Non-Hormonal Menopause Treatment

• 💡 The FDA has approved a new daily pill, Veozah (fezolinetant), as a non-hormonal treatment for hot flashes and night sweats associated with menopause.
• 🎯 This medication targets brain pathways that regulate body temperature, offering an alternative for women who cannot or choose not to use hormone therapy.

How Veozah Works

• 🧠 The drug works by antagonizing two specific receptors in the brain: ENK1 and ENK3.
• 🔬 By modulating these receptors, it effectively decreases the frequency and severity of hot flashes.

Potential Side Effects and Contraindications

• ⚠️ While generally well-tolerated, potential side effects include headaches, arthritis, sleepiness, or dizziness.
• 🚫 There were no clinically significant liver test elevations or liver toxicity observed in trials, and no effect on cancers.
• ⚠️ The medication is not approved for pregnant women and should not be taken by individuals with liver issues.

Availability and Cost

• 🗓️ Veozah is a prescription medication expected to be available by the end of the year.
• 💰 The marketing price is over $600, but efforts are underway with Bayer to reduce costs through insurance or savings programs.
• 👩‍⚕️ Women will need to consult with their healthcare provider to determine if they are a good candidate.

Broader Impact on Menopause Care

• ✨ The approval is considered exciting for providing an effective and safe tested therapy for women who cannot use hormone therapy.
• 📈 Clinical trials also indicated improvements in mood and sleep in addition to reducing hot flashes and night sweats.
• 🤝 This new option offers hope for women experiencing significant discomfort from menopause, including those with natural or surgical menopause, or those undergoing endocrine therapy for breast cancer.